Analyst Ratings for BioXcel Therapeutics (BTAI)
BTAI Rating Summary
BTAI Price Target Summary
- Highest: $66.00 (Lucid Capital Markets)
- Lowest: $4.00 (Mizuho)
- Average: $23.00
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$23.00 (+1816.7%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 52%
Avg. $ Target:
$23.00 (+1816.7%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 52%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/17/2026 | Rodman & Renshaw | Michael King Jr. | New Coverage | Buy (N/A) |
17.00 (N/A) |
1.54 (1.20) |
-22.08% | Details |
| 6/25/2025 | Lucid Capital Markets | N/A | New Coverage | Buy (N/A) |
66.00 (N/A) |
1.73 (1.20) |
-30.64% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
